Skip to main content
SpringerLink
Log in

Erlotinib

Acquired resistance to erlotinib during treatment for non small cell lung carcinoma with epidermal growth factor receptor (EGFR) mutation: case report

  • Case report
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Reference

  • Mistry R, et al. Importance of repeat tissue biopsy and tissue-based epidermal growth factor receptor T790M testing in progressed nonsmall cell lung carcinoma patients upon negative plasma genotyping for selection of third-generation tyrosine kinase inhibitor therapy: A case study. Indian Journal of Cancer 54 (Suppl.): s65-s66, No. 5, Dec 2017. Available from: URL: http://doi.org/10.4103/ijc.IJC_545_17 - India

    Article  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Erlotinib. Reactions Weekly 1717, 129 (2018). https://doi.org/10.1007/s40278-018-51199-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-018-51199-y

Search

Navigation